A citation-based method for searching scientific literature

Nitin A Das, Andrea J Carpenter, Anthony Belenchia, Annayya R Aroor, Makoto Noda, Ulrich Siebenlist, Bysani Chandrasekar, Vincent G DeMarco. Cell Signal 2020
Times Cited: 23







List of co-cited articles
143 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
21

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
17

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
17

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
17

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
560
17

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
17

Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy.
Hari Krishan Aggarwal, Deepak Jain, Paulomi Talapatra, Raj Kumar Yadav, Tarana Gupta, Kashmiri Lal Kathuria. Ren Fail 2010
25
13

Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data.
Kunihiro Matsushita, Josef Coresh, Yingying Sang, John Chalmers, Caroline Fox, Eliseo Guallar, Tazeen Jafar, Simerjot K Jassal, Gijs W D Landman, Paul Muntner,[...]. Lancet Diabetes Endocrinol 2015
330
13

Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: multicentre prospective study in nephrology clinics.
Michele Provenzano, Paolo Chiodini, Roberto Minutolo, Carmine Zoccali, Vincenzo Bellizzi, Giuseppe Conte, Francesco Locatelli, Giovanni Tripepi, Lucia Del Vecchio, Francesca Mallamaci,[...]. Nephrol Dial Transplant 2020
26
13

Epidemiology of low-proteinuric chronic kidney disease in renal clinics.
Luca De Nicola, Michele Provenzano, Paolo Chiodini, Silvio Borrelli, Luigi Russo, Antonio Bellasi, Domenico Santoro, Giuseppe Conte, Roberto Minutolo. PLoS One 2017
21
14

Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy.
Anneli Lauhio, Timo Sorsa, Ravi Srinivas, Mathias Stenman, Taina Tervahartiala, Ulf-Håkan Stenman, Carola Grönhagen-Riska, Eero Honkanen. Ann Med 2008
35
13

Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale.
Michele Provenzano, Giuseppe Coppolino, Luca De Nicola, Raffaele Serra, Carlo Garofalo, Michele Andreucci, Davide Bolignano. Front Cell Dev Biol 2019
40
13


The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity.
Matthias Oelze, Swenja Kröller-Schön, Philipp Welschof, Thomas Jansen, Michael Hausding, Yuliya Mikhed, Paul Stamm, Michael Mader, Elena Zinßius, Saule Agdauletova,[...]. PLoS One 2014
150
13

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Hiddo J L Heerspink, Hans-Henrik Parving, Dennis L Andress, George Bakris, Ricardo Correa-Rotter, Fan-Fan Hou, Dalane W Kitzman, Donald Kohan, Hirofumi Makino, John J V McMurray,[...]. Lancet 2019
174
13

Pathophysiology of the diabetic kidney.
Volker Vallon, Radko Komers. Compr Physiol 2011
107
13

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
13

SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE.
Xiaoxin X Wang, Jonathan Levi, Yuhuan Luo, Komuraiah Myakala, Michal Herman-Edelstein, Liru Qiu, Dong Wang, Yingqiong Peng, Almut Grenz, Scott Lucia,[...]. J Biol Chem 2017
137
13

Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells.
Chenke Xu, Wei Wang, Jin Zhong, Fan Lei, Naihan Xu, Yaou Zhang, Weidong Xie. Biochem Pharmacol 2018
58
13

Diabetes and Kidney Disease: Role of Oxidative Stress.
Jay C Jha, Claudine Banal, Bryna S M Chow, Mark E Cooper, Karin Jandeleit-Dahm. Antioxid Redox Signal 2016
188
13


Matrix metalloproteinases in kidney homeostasis and diseases.
Roderick J Tan, Youhua Liu. Am J Physiol Renal Physiol 2012
149
8

Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study.
Johan Sundström, Jane C Evans, Emelia J Benjamin, Daniel Levy, Martin G Larson, Douglas B Sawyer, Deborah A Siwik, Wilson S Colucci, Peter W F Wilson, Ramachandran S Vasan. Eur Heart J 2004
120
8

Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?
M Peiskerová, M Kalousová, M Kratochvílová, S Dusilová-Sulková, J Uhrová, S Bandúr, I M Malbohan, T Zima, V Tesar. Kidney Blood Press Res 2009
23
8

Matrix metalloproteinases in vascular disease--a potential therapeutic target?
Chung S Lim, Joseph Shalhoub, Manjit S Gohel, Armanda C Shepherd, Alun H Davies. Curr Vasc Pharmacol 2010
53
8

Structure and function of matrix metalloproteinases and TIMPs.
Hideaki Nagase, Robert Visse, Gillian Murphy. Cardiovasc Res 2006
8

Matrix metalloproteinases in subjects with type 1 diabetes.
Sedegheh Gharagozlian, Katja Svennevig, Hans-Jacob Bangstad, Jan-Olof Winberg, Svein Olav Kolset. BMC Clin Pathol 2009
48
8

Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data.
Kunihiro Matsushita, Shoshana H Ballew, Josef Coresh, Hisatomi Arima, Johan Ärnlöv, Massimo Cirillo, Natalie Ebert, Jade S Hiramoto, Heejin Kimm, Michael G Shlipak,[...]. Lancet Diabetes Endocrinol 2017
59
8



Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation.
P Rouet-Benzineb, J M Buhler, P Dreyfus, A Delcourt, R Dorent, J Perennec, B Crozatier, A Harf, C Lafuma. Eur J Heart Fail 1999
101
8

Prognostic role of LDL cholesterol in non-dialysis chronic kidney disease: Multicenter prospective study in Italy.
Luca De Nicola, Michele Provenzano, Paolo Chiodini, Graziella D'Arrigo, Giovanni Tripepi, Lucia Del Vecchio, Giuseppe Conte, Francesco Locatelli, Carmine Zoccali, Roberto Minutolo. Nutr Metab Cardiovasc Dis 2015
17
11

Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy.
Kyoichi Tashiro, Ichiro Koyanagi, Ikko Ohara, Takamichi Ito, Akemi Saitoh, Satoshi Horikoshi, Yasuhiko Tomino. J Clin Lab Anal 2004
49
8

Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis.
K Steinmann-Niggli, R Ziswiler, M Küng, H P Marti. J Am Soc Nephrol 1998
86
8

Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.
Ron T Gansevoort, Kunihiro Matsushita, Marije van der Velde, Brad C Astor, Mark Woodward, Andrew S Levey, Paul E de Jong, Josef Coresh. Kidney Int 2011
469
8


Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis.
Navdeep Tangri, Morgan E Grams, Andrew S Levey, Josef Coresh, Lawrence J Appel, Brad C Astor, Gabriel Chodick, Allan J Collins, Ognjenka Djurdjev, C Raina Elley,[...]. JAMA 2016
221
8


Variability in response to albuminuria-lowering drugs: true or random?
Sergei I Petrykiv, Dick de Zeeuw, Frederik Persson, Peter Rossing, Ron T Gansevoort, Gozewijn D Laverman, Hiddo J L Heerspink. Br J Clin Pharmacol 2017
14
14

Cardiorenal prognosis by residual proteinuria level in diabetic chronic kidney disease: pooled analysis of four cohort studies.
Roberto Minutolo, Francis B Gabbai, Michele Provenzano, Paolo Chiodini, Silvio Borrelli, Carlo Garofalo, Ferdinando C Sasso, Domenico Santoro, Vincenzo Bellizzi, Giuseppe Conte,[...]. Nephrol Dial Transplant 2018
53
8

Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury.
Sunfa Cheng, Allan S Pollock, Rajeev Mahimkar, Jean L Olson, David H Lovett. FASEB J 2006
178
8

Impact of BMI on cardiovascular events, renal function, and coronary artery calcification.
Domenico Russo, Luigi Francesco Morrone, Carmela Errichiello, Maria Grazia De Gregorio, Massimo Imbriaco, Yuri Battaglia, Luigi Russo, Michele Andreucci, Biagio Raffaele Di Iorio. Blood Purif 2014
13
15

Differential expression of MMP-2/MMP-9 and potential benefit of an MMP inhibitor in experimental acute kidney allograft rejection.
Monica Ermolli, Martin Schumacher, Nadège Lods, Mahmoud Hammoud, Hans Peter Marti. Transpl Immunol 2003
31
8


Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall.
K M Newman, J Jean-Claude, H Li, J V Scholes, Y Ogata, H Nagase, M D Tilson. J Vasc Surg 1994
178
8

Subclinical atherosclerosis measures for cardiovascular prediction in CKD.
Kunihiro Matsushita, Yingying Sang, Shoshana H Ballew, Michael Shlipak, Ronit Katz, Sylvia E Rosas, Carmen A Peralta, Mark Woodward, Holly J Kramer, David R Jacobs,[...]. J Am Soc Nephrol 2015
72
8

Matrix Metalloproteinases in Renal Diseases: A Critical Appraisal.
Oskar Zakiyanov, Marta Kalousová, Tomáš Zima, Vladimír Tesař. Kidney Blood Press Res 2019
33
8



Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress.
Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva. Mol Cell Endocrinol 2019
16
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.